Skip to content

Navigation

  • Map
  • Episodes
  • Articles
  • Advertise
  • About Us
  • Subscribe Free

Social

YouTube Spotify Apple Podcasts
  • Map
  • Episodes
  • Articles
  • Advertise
  • About Us
Subscribe Free
background-splash
podcast-artwork

All Episodes

Listen to the top Europeans in Biotech.

Youtube
Spotify
Apple Podcasts
Camurus CEO Fredrik Tiberg on Long-Acting Opioid Treatment

Camurus CEO Fredrik Tiberg on Long-Acting Opioid Treatment

Turning Generics Into Game-Changing Therapies: Fredrik Tiberg of Camurus Explains the Power of Long-Acting Medicines...
Philip Hemme
Philip Hemme
Camurusdrug development
• Feb 24, 2026
Personalized Cancer Vaccines and Oncolytic Viruses: The Next Generation of Cancer Immunotherapy

Personalized Cancer Vaccines and Oncolytic Viruses: The Next Generation of Cancer Immunotherapy

For decades, cancer vaccines have promised much and delivered little. Early “off-the-shelf” approaches struggled to...
Philip Hemme
Philip Hemme
Alessandro Rivacancer
• Jan 27, 2026
From Breakthrough to Maturity: How Cell Therapy Is Evolving

From Breakthrough to Maturity: How Cell Therapy Is Evolving

Cell therapy has come a long way in just over a decade. What began as...
Philip Hemme
Philip Hemme
cell therapyJeito
• Jan 20, 2026
Why Vaccines Still Matter: Valneva CEO Thomas Lingelbach

Why Vaccines Still Matter: Valneva CEO Thomas Lingelbach

Few areas of healthcare have saved more lives, or generated more debate, than vaccines. For...
Philip Hemme
Philip Hemme
biotech companiesvaccines
• Jan 14, 2026
Abivax’s Record NASDAQ Stock Surge After Phase 3 Data

Abivax’s Record NASDAQ Stock Surge After Phase 3 Data

In biotech, Phase 3 data can change everything, or end everything. Few stories capture that...
Philip Hemme
Philip Hemme
biotech valuation jumpsdrug development execution
• Dec 21, 2025
Free Database of the Top 100 Public Biotechs in Europe

Free Database of the Top 100 Public Biotechs in Europe

The FlotBio Map is live at map.flot.bio 🙌 Here’s a bit of background FlotBio Map...
Philip Hemme
Philip Hemme
biotech companies
• Dec 21, 2025
Why AI in Biopharma Didn’t Live Up to the Hype

Why AI in Biopharma Didn’t Live Up to the Hype

AI has reshaped entire industries, from software development to entertainment, yet its impact in healthcare...
Philip Hemme
Philip Hemme
AIdrug development
• Dec 3, 2025
Why ADCs and Radiopharmaceuticals Are Big Pharma’s New Obsession

Why ADCs and Radiopharmaceuticals Are Big Pharma’s New Obsession

Antibody-drug conjugates (ADCs) and radiopharmaceuticals have moved from the fringes of biotech buzzwords into the...
Philip Hemme
Philip Hemme
ADCsadvanced therapeutics
• Aug 8, 2025
Baker Brothers’ Biotech Investing Secrets

Baker Brothers’ Biotech Investing Secrets

In a biotech landscape dominated by hype and volatility, the Baker Brothers have emerged as...
Philip Hemme
Philip Hemme
Baker Brothersbiotech investing
• Jul 21, 2025
The 25 Most Valuable Biotech Companies in Europe in 2025

The 25 Most Valuable Biotech Companies in Europe in 2025

The biotech industry in Europe is booming, with companies making groundbreaking medical advances, from oncology...
Philip Hemme
Philip Hemme
argenxAscendis Pharma
• May 19, 2025

« 1 2

Never Miss a New Episode 💌

Trusted by 2500+ biopharma professionals from top companies like argenx, Roche, and Forbion. No spam, no noise.

By subscribing you agree to our privacy policy.

Watch & Subscribe

Flot.bio on Youtube Flot.bio on Spotify Flot.bio on Apple Podcasts
Flot.bio
  • Map
  • Episodes
  • Articles
  • About Us
  • Donate
  • Media Kit
  • Subscribe Free

Contact us via Katherine: hi@flot.bio

Follow Us:

Latest Episode:
Billionaire wild bets on Consumer Biotech, GLP-1s, and psychedelics | Christian Angermayer | E61
Latest Article:
Consumer Biotech’s Next Wave: Muscle, Sex, and Psychedelics
Flot.bio © 2026
Made with ❤ in Europe 🇪🇺
  • Imprint
  • Privacy Policy